Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EMMAUS LIFE SCIENCES, INC.NONE · Entity 156030 | Director · Chairman and CEO · 10% owner | July 09, 2019 | July 11, 2019 |
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director · Chairman and CEO · 10% owner | January 12, 2023 | January 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EMMAUS LIFE SCIENCES, INC.
Report date July 09, 2019 · Filed July 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Promissory Note dated 9/14/17, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | Direct | 1 |
Reported balance
After 2019-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. |
| Promissory Note dated 3/6/16, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | IndirectBy Hope International Hospice, Inc. | 1 |
Reported balance
After 2019-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown. |
Filing footnotes · ownership attribution and instrument terms
F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc.
F2: See footnote 1.
F3: Represents the outside date for completion of the proposed merger, unless extended by the parties.
F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction.
F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown.
Emmaus Life Sciences, Inc.
Report date January 12, 2023 · Filed January 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2028-01-11 | Direct | 0 |
Reported balance
After 2023-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-12 · Grant · Acquired 7,500,000 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2023 Filed Jan 17, 2023 18:59 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | GrantWarrants (right to buy) · Derivative | 7,500,000 | $4.50 Strike: $4.50 | $33,750,000.00 |
DisclosureSEC source: 0001209191-23-003457 · doc4.xml · derivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500,000 shares Expires 2028-01-11 Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 18:35 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 22,900 | $0.41 | $9,389.00 |
DisclosureSEC source: 0001209191-22-059154 · doc4.xml · nonDerivative · entry 5 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,040,857 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.44, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 18:35 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 14,700 | $0.38 | $5,586.00 |
DisclosureSEC source: 0001209191-22-059154 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,017,957 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.36 to $0.40, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 28, 2022 Filed Dec 1, 2022 18:35 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $0.35 | $1,750.00 |
DisclosureSEC source: 0001209191-22-059154 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,003,257 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 04, 2022 Filed Dec 1, 2022 18:35 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,500 | $0.45 | $3,375.00 |
DisclosureSEC source: 0001209191-22-059154 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,998,257 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.45 to $0.46, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) and in footnotes (3) and (4) to this Form 4. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 03, 2022 Filed Dec 1, 2022 18:35 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,500 | $0.45 | $1,125.00 |
DisclosureSEC source: 0001209191-22-059154 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,990,757 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 18:50 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 15,000 | $0.43 | $6,450.00 |
DisclosureSEC source: 0001209191-22-055471 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,988,257 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.42 to $0.45, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 18:50 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $0.43 | $2,150.00 |
DisclosureSEC source: 0001209191-22-055471 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,973,257 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.42 to $0.44, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 18:50 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,500 | $0.45 | $3,375.00 |
DisclosureSEC source: 0001209191-22-055471 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,968,257 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.44 to $0.46, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 18:59 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,500 | $0.42 | $3,150.00 |
DisclosureSEC source: 0001209191-22-054902 · doc4.xml · nonDerivative · entry 5 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,960,757 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.40 to $0.47, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 18:59 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 22,500 | $0.27 | $6,075.00 |
DisclosureSEC source: 0001209191-22-054902 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,953,257 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.26 to $0.35, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 26, 2022 Filed Oct 31, 2022 18:59 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 11,900 | $0.27 | $3,213.00 |
DisclosureSEC source: 0001209191-22-054902 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,930,757 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.25 to $0.35, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) and in footnotes (3) and (4) to this Form 4. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 25, 2022 Filed Oct 31, 2022 18:59 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 20,000 | $0.26 | $5,200.00 |
DisclosureSEC source: 0001209191-22-054902 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,918,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 24, 2022 Filed Oct 31, 2022 18:59 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,500 | $0.22 | $1,650.00 |
DisclosureSEC source: 0001209191-22-054902 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,898,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 22:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 10,000 | $0.19 | $1,900.00 |
DisclosureSEC source: 0001209191-22-054449 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,891,357 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 22:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 30,000 | $0.18 | $5,400.00 |
DisclosureSEC source: 0001209191-22-054449 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,881,357 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.17 to $0.21, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 19, 2022 Filed Oct 24, 2022 22:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 25,000 | $0.16 | $4,000.00 |
DisclosureSEC source: 0001209191-22-054449 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,851,357 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.15 to $0.20, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 18:21 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 30,000 | $0.19 | $5,700.00 |
DisclosureSEC source: 0001209191-22-054051 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,826,357 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.17 to $0.20, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 18:21 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 15,000 | $0.20 | $3,000.00 |
DisclosureSEC source: 0001209191-22-054051 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796,357 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.20 to $0.22, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 14, 2022 Filed Oct 17, 2022 17:01 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 35,000 | $0.17 | $5,950.00 |
DisclosureSEC source: 0001209191-22-053757 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,781,357 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.15 to $0.18, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 17:01 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 62,500 | $0.18 | $11,250.00 |
DisclosureSEC source: 0001209191-22-053757 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,746,357 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.10 to $0.31, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 20:05 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 160,000 | $0.08 | $12,800.00 |
DisclosureSEC source: 0001209191-22-053559 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,683,857 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.07 to $0.09, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2). F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 11, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 130,000 | $0.09 | $11,700.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 9 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,518,857 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.08 to $0.12, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2). F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 20:05 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $0.09 | $450.00 |
DisclosureSEC source: 0001209191-22-053559 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,523,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 10,000 | $0.09 | $900.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 8 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,388,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 07, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $0.13 | $520.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 7 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,378,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 06, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $0.15 | $750.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 6 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,374,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 05, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 10,000 | $0.15 | $1,500.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 5 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,369,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 04, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $0.16 | $800.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,359,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 03, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 10,000 | $0.20 | $2,000.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,354,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 27, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $0.20 | $1,000.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,344,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 26, 2022 Filed Oct 12, 2022 17:04 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,000 | $0.20 | $1,200.00 |
DisclosureSEC source: 0001209191-22-053433 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,339,857 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 23, 2022 Filed Jun 2, 2022 23:49 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $0.50 | $1,000.00 |
DisclosureSEC source: 0001209191-22-033730 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,333,857 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 20, 2022 Filed Jun 2, 2022 23:49 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $0.49 | $2,450.00 |
DisclosureSEC source: 0001209191-22-033730 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,331,857 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.48 to $0.50, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 18, 2022 Filed May 19, 2022 18:45 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,351 | $0.35 | $2,572.85 |
DisclosureSEC source: 0001209191-22-030451 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,326,857 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.28 to $0.40, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 13, 2022 Filed May 19, 2022 18:45 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 10,000 | $0.34 | $3,400.00 |
DisclosureSEC source: 0001209191-22-030451 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,319,506 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.33 to $0.35, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) and in footnote (3) to this Form 4. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 09, 2022 Filed May 19, 2022 18:45 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,000 | $0.60 | $3,600.00 |
DisclosureSEC source: 0001209191-22-030451 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309,506 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:55 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 53,800 | $1.49 | $80,162.00 |
DisclosureSEC source: 0001209191-22-014998 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,303,506 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.43 to $1.70, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 17:26 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,500 | $1.41 | $7,755.00 |
DisclosureSEC source: 0001209191-22-013475 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,249,706 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.41 to $1.45, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 17:26 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 11,000 | $1.43 | $15,730.00 |
DisclosureSEC source: 0001209191-22-013475 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,244,206 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.43 to $1.45, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 16:56 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 17,800 | $1.44 | $25,632.00 |
DisclosureSEC source: 0001209191-22-012064 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,233,206 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.45, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:56 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.43 | $2,145.00 |
DisclosureSEC source: 0001209191-22-012064 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,215,406 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.45, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 18:01 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,500 | $1.43 | $9,295.00 |
DisclosureSEC source: 0001209191-22-011119 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,213,906 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.47, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 18:01 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.47 | $1,470.00 |
DisclosureSEC source: 0001209191-22-011119 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,207,406 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.44 to $1.47, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 20:01 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,000 | $1.45 | $8,700.00 |
DisclosureSEC source: 0001209191-22-010142 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,206,406 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.43 to $1.45, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 20:01 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,000 | $1.45 | $8,700.00 |
DisclosureSEC source: 0001209191-22-010142 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200,406 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.44 to $1.49, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 11, 2022 Filed Feb 11, 2022 22:00 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $1.49 | $5,960.00 |
DisclosureSEC source: 0001209191-22-008917 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,194,406 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 22:00 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,000 | $1.45 | $4,350.00 |
DisclosureSEC source: 0001209191-22-008917 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,190,406 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:00 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 23,500 | $1.45 | $34,075.00 |
DisclosureSEC source: 0001209191-22-008917 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,187,406 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.40 to $1.49, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 18:57 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,250 | $1.49 | $4,842.50 |
DisclosureSEC source: 0001209191-22-007990 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,163,906 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.50, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.